# Time-Dependent DCE-MRI Radiomics to Predict Response to Neoadjuvant Therapy in Breast Cancer: A Multicenter Study with External Validation

**Authors:** Giulia Vatteroni, Riccardo Levi, Paola Nardi, Giulia Pruneddu, Elisa Salpietro, Federica Fici, Cinzia Monti, Rubina Manuela Trimboli, Daniela Bernardi

PMC · DOI: 10.3390/diagnostics16040611 · 2026-02-19

## TL;DR

This study shows that using time-dependent MRI features can accurately predict how breast cancer patients will respond to neoadjuvant therapy, especially in identifying non-responders.

## Contribution

The study introduces time-dependent radiomic features from DCE-MRI to improve prediction of neoadjuvant therapy response in breast cancer.

## Key findings

- Time-dependent texture features were significantly associated with non-response to therapy.
- The model achieved high AUC values in predicting pathological responses, especially for non-responders.
- The approach performed well in both internal and external validation cohorts.

## Abstract

Background: The accurate prediction of response to neoadjuvant therapy (NAT) is crucial for optimizing breast cancer management. Conventional breast Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) radiomics typically relies on single post-contrast phases and may not fully capture temporal enhancement patterns related to tumor heterogeneity. This study evaluated a machine learning model based on time-dependent radiomic features extracted from pre-treatment DCE-MRI for predicting NAT response in breast cancer patients. Methods: Breast DCE-MRI examinations of women scheduled for NAT, acquired on 1.5 T scanners from three different vendors, were retrospectively collected from two centers. Tumors were automatically segmented on the third post-contrast DCE image using a 3D nnUNet model trained on 30 lesions. All DCE phases were registered to the reference image, and radiomic features were extracted from a consistent tumor region of interest across all phases. Time-dependent radiomic features were computed using linear regression modeling of feature evolution over time. A random forest classifier integrating static and time-dependent radiomic features was developed to predict pathological complete response (pCR), partial response (pPR), and non-response (pNR). Model performance was evaluated using internal validation (Center 1) and an independent external test cohort (Center 2). Results: A total of 212 patients were included (173 from Center 1 and 39 from Center 2), comprising 103 pCR, 103 pPR and 6 pNR cases. Among 759 extracted features, 30 showed significant differences across response groups. Several time-dependent texture features related to intratumoral heterogeneity were significantly associated with pNR. The model achieved AUC values of 0.80, 0.81, and 0.95 in the internal validation cohort and 0.75, 0.74, and 0.86 in the external test cohort for predicting pCR, pPR, and pNR, respectively. Conclusions: Time-dependent radiomic features derived from pre-treatment breast DCE-MRI enable the accurate prediction of response to NAT, with particularly strong performance in identifying non-responders. This approach may support imaging-based risk stratification and contribute to more personalized treatment.

## Linked entities

- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, NR4A1 (nuclear receptor subfamily 4 group A member 1) [NCBI Gene 3164] {aka GFRP1, HMR, N10, NAK-1, NGFIB, NP10}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, PPR1 (Photoparoxysmal response 1) [NCBI Gene 100528023] {aka PPR}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}
- **Diseases:** fat (MESH:D004620), node (MESH:D012804), injury to (MESH:D014947), Luminal B (MESH:D006509), DCIS ductal carcinoma in situ (MESH:D002285), Cancer (MESH:D009369), hypersensitivity (MESH:D004342), pCR (MESH:D005598), Triple-negative breast cancer (MESH:D064726), Breast Cancer (MESH:D001943), invasive ductal carcinoma (MESH:D044584), Invasive Carcinoma (MESH:D009361), malignant breast lesion (MESH:D001941), neutropenia (MESH:D009503), invasive cancer (MESH:D009362), toxicity (MESH:D064420), atrial fibrillation (MESH:D001281)
- **Chemicals:** pertuzumab (MESH:C485206), Cyclophosphamide (MESH:D003520), anthracycline (MESH:D018943), trastuzumab (MESH:D000068878), AC (MESH:D000186), taxane (MESH:C080625), Gadobutrol (MESH:C090600), carboplatin (MESH:D016190), Doxorubicin (MESH:D004317), DCE (-), pembrolizumab (MESH:C582435)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939715/full.md

---
Source: https://tomesphere.com/paper/PMC12939715